Literature DB >> 3335308

Medical management of patients with Zollinger-Ellison syndrome who have had previous gastric surgery: a prospective study.

P N Maton1, H Frucht, R Vinayek, S A Wank, J D Gardner, R T Jensen.   

Abstract

We examined prospectively the criteria for medical management in 16 patients with Zollinger-Ellison syndrome who had had previous gastric surgery. Each patient received sufficient antisecretory medication to lower gastric acid output to less than 10 mEq/h during the last hour before the next dose of drug. The 7 patients with a vagotomy but no gastric resection were symptom-free and had no mucosal disease. Of 9 patients with a partial gastrectomy, 7 had mucosal disease, with or without symptoms, and 6 of the 7 patients had acid outputs of 5-10 mEq/h. In these patients, antisecretory medication was increased to reduce output to less than 5 mEq/h and symptoms and mucosal abnormalities resolved in each patient. Patients with Zollinger-Ellison syndrome and a vagotomy can be treated safely by reducing acid secretion to less than 10 mEq/h, but in patients with a partial gastrectomy, acid secretion must be reduced to less than 5 mEq/h, and adequacy of therapy must be checked further by endoscopy.

Entities:  

Mesh:

Substances:

Year:  1988        PMID: 3335308     DOI: 10.1016/0016-5085(88)90415-5

Source DB:  PubMed          Journal:  Gastroenterology        ISSN: 0016-5085            Impact factor:   22.682


  21 in total

1.  NANETS treatment guidelines: well-differentiated neuroendocrine tumors of the stomach and pancreas.

Authors:  Matthew H Kulke; Lowell B Anthony; David L Bushnell; Wouter W de Herder; Stanley J Goldsmith; David S Klimstra; Stephen J Marx; Janice L Pasieka; Rodney F Pommier; James C Yao; Robert T Jensen
Journal:  Pancreas       Date:  2010-08       Impact factor: 3.327

Review 2.  Diagnosis of Zollinger-Ellison syndrome: increasingly difficult.

Authors:  Tetsuhide Ito; Guillaume Cadiot; Robert T Jensen
Journal:  World J Gastroenterol       Date:  2012-10-21       Impact factor: 5.742

Review 3.  Famotidine. An updated review of its pharmacodynamic and pharmacokinetic properties, and therapeutic use in peptic ulcer disease and other allied diseases.

Authors:  H D Langtry; S M Grant; K L Goa
Journal:  Drugs       Date:  1989-10       Impact factor: 9.546

Review 4.  Use of omeprazole in patients with Zollinger-Ellison syndrome.

Authors:  H Frucht; P N Maton; R T Jensen
Journal:  Dig Dis Sci       Date:  1991-04       Impact factor: 3.199

5.  Parenteral control of gastric acid hypersecretion in patients with Zollinger-Ellison syndrome.

Authors:  R Vinayek; W F Hahne; A R Euler; J A Norton; R T Jensen
Journal:  Dig Dis Sci       Date:  1993-10       Impact factor: 3.199

Review 6.  Optimal treatment of Zollinger-Ellison syndrome and related conditions in elderly patients.

Authors:  Paola Tomassetti; Teresa Salomone; Marina Migliori; Davide Campana; Roberto Corinaldesi
Journal:  Drugs Aging       Date:  2003       Impact factor: 3.923

7.  A prospective study of gastric carcinoids and enterochromaffin-like cell changes in multiple endocrine neoplasia type 1 and Zollinger-Ellison syndrome: identification of risk factors.

Authors:  Marc J Berna; Bruno Annibale; Massimo Marignani; Tu Vinh Luong; Vito Corleto; Andrea Pace; Tetsuhide Ito; David Liewehr; David J Venzon; Gianfranco Delle Fave; Cesare Bordi; Robert T Jensen
Journal:  J Clin Endocrinol Metab       Date:  2008-02-12       Impact factor: 5.958

Review 8.  Gastrointestinal neuroendocrine tumors: pancreatic endocrine tumors.

Authors:  David C Metz; Robert T Jensen
Journal:  Gastroenterology       Date:  2008-08-12       Impact factor: 22.682

9.  Curative resection in Zollinger-Ellison syndrome. Results of a 10-year prospective study.

Authors:  J A Norton; J L Doppman; R T Jensen
Journal:  Ann Surg       Date:  1992-01       Impact factor: 12.969

10.  Peptic ulcer perforation as the presentation of Zollinger-Ellison syndrome.

Authors:  I Waxman; J D Gardner; R T Jensen; P N Maton
Journal:  Dig Dis Sci       Date:  1991-01       Impact factor: 3.199

View more

北京卡尤迪生物科技股份有限公司 © 2022-2023.